By Stephen Hansen, Senior Writer
from concept to approved drug for MannKind
Corp.'s Afrezza inhaled insulin is one beset by multiple
regulatory setbacks that saw the company - the brainchild of serial
entrepreneur, Chairman and CEO Alfred Mann - burn through more than $1.6
billion in cash over the past 12 years.
company has sustained itself with Mann's deep pockets. Mann and his entities
owned 40% of MannKind as of March 21. And as of March 31, the company also owed
the Mann Group $49.5 million under a loan arrangement.